date:Jul 19, 2012
s that a product treats, prevents or reduces the risk of diseases, only RCTs will do,it concludes.
But writing in the FDA law blog yesterday, Hyman, Phelps McNamara attorney Ritte van Laack notes that the FTC also stresses that the requirement for RCTs applies to disease efficacy claims and its statements shouldnotbe interpreted to mean that RCTs are automatically required foranyhealth efficacy claims.
POM: Our claims are all supported by science
In its appeal, POM defends its science and sa